Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study
The Lancet Global Health
16 August 2024 /open access/
-- Accompanying comment: The potential distraction of a pan-regimen approach to tuberculosis
/open access/
**************
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
The Lancet Infectious Diseases
September 2024 /open access/
-- Accompanying comment: A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis
/open access/
**************
Global, regional, and national burden of HIV-negative tuberculosis, 1990–2021: findings from the Global Burden of Disease Study 2021
Infectious Diseases of Poverty
19 August 2024 /open access/
**************
Epidemiological features and temporal trends of the co-infection between HIV and tuberculosis, 1990–2021: findings from the Global Burden of Disease Study 2021
Infectious Diseases of Poverty
16 August 2024 /open access/
**************
Nationwide surveys of awareness of tuberculosis in India uncover a gender gap in tuberculosis awareness
Communications Medicine
23 August 2024 /open access/
**************
The performance of digital technologies for measuring tuberculosis medication adherence: a systematic review
BMJ Global Health
16 July 2024 /open access/
**************
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
The Lancet Infectious Diseases
August 2024 /open access/
-- Accompanying comment: A new tool for accelerating tuberculosis vaccine development
/open access/
**************
Association between HIV and acquisition of rifamycin resistance with first-line TB treatment: a systematic review and meta-analysis
BMC Infectious Diseases
1 July 2024 /open access/
**************
Beyond the diagnosis of drug-resistant Tuberculosis in Norway: patients’ experiences before, during and after treatment
BMC Public Health
6 July 2024 /open access/
**************
Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024
Globalization and Health
25 June 2024 /open access/
**************